Exelixis' zanzalintinib misses OS endpoint in mCRC subgroup without liver mets; FDA decision on all-comers approval due Dec 3.
Despite the success of Exelixis’ oral tyrosine kinase inhibitor in a broader population, the candidate failed to significantly improve survival in colorectal cancer patients without …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metastatic colorectal cancer…
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in…
Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares…
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
Upfront treatment options set to expand for NSCLC patients with EGFR exon 20 insertions
Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase…
